The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM).
Rahima Jamal
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Karl Belanger
No relevant relationships to disclose
Jennifer Elisabeth Friedmann
No relevant relationships to disclose
Jean-Pierre M. Ayoub
Consultant or Advisory Role - Bristol-Myers Squibb
Eftihia Cocolakis
No relevant relationships to disclose
Shirin Kazemi
No relevant relationships to disclose
Jeanne Dionne
No relevant relationships to disclose
Caroline Lambert
No relevant relationships to disclose
HB Le
No relevant relationships to disclose
Leon Van Kempen
No relevant relationships to disclose
Alan Spatz
No relevant relationships to disclose
Rejean Lapointe
No relevant relationships to disclose
Wilson H. Miller
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb